Shares of IndiaMart Intermesh jumped over 6% to Rs 2,650 on Tuesday after Nuvama Institutional Equities upgraded the stock to ‘Buy’ from ‘Reduce’ and raised the target price to Rs 3,800 ...

Indiamart Intermesh shares rose 6.5% to ₹2,655, reaching an 8-month high. The increase followed an upgrade from Nuvama Institutional Equities, which raised its rating to 'buy' and target price ...

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

IndiaMART InterMESH settled at Rs 2,500 apiece on Tuesday. Nuvama's fresh target price suggests 52 per cent upside over this price.

MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its ...

Pharmaceutical giant Merck will close its plant in Northumberland County, Pennsylvania. According to a WARN Notice filed with the state's Department of Labor and Industry, three rounds of layoffs ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, with GEN Edge.

Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

RAHWAY, N.J., June 24, 2025--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.